[1] BRENT G A. Mechanisms of thyroid hormone action[J/OL]. The Journal of Clinical Investigation, 2012, 122(9): 3035-3043. DOI:10.1172/JCI60047.
[2] SIBILIO A, AMBROSIO R, BONELLI C, et al. Deiodination in cancer growth: the role of type III deiodinase[J]. Minerva endocrinologica, 2012, 37(4): 315-327.
[3] SOGAARD M, FARKAS D K, EHRENSTEIN V, et al. Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study[J]. European journal of endocrinology, 2016, 174(4): 409-414.DOI:10.1530/eje-15-0989
[4] WAHDAN-ALASWAD R S, EDGERTON S M, KIM H M, et al. Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer[J/OL]. Cell Cycle, 2023: 1-20.DOI:10.1080/15384101.2023.2249702.
[5] YANG H, HOLOWKO N, GRASSMANN F, et al. Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors[J]. BMC medicine, 2020, 18: 1-10.DOI:10.1186/s12916-020-01690-y.
[6] TRAN T V T, MARINGE C, BENITEZ MAJANO S, et al. Thyroid dysfunction and breast cancer risk among women in the UK Biobank cohort[J/OL]. Cancer Medicine, 2021, 10(13): 4604-4614. DOI:10.1002/cam4.3978.
[7] METSO S, AUVINEN A, HUHTALA H, et al. Increased cancer incidence after radioiodine treatment for hyperthyroidism[J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2007, 109(10): 1972-1979.DOI:10.1002/cncr.22635.
[8] YUAN S, KAR S, VITHAYATHIL M, et al. Causal associations of thyroid function and dysfunction with overall, breast and thyroid cancer: A two‐sample Mendelian randomization study[J].International journal of cancer, 2020, 147(7): 1895-1903.DOI:10.1002/ijc.32988.
[9] ANGELOUSI A G, ANAGNOSTOU V K, STAMATAKOS M K, et al. Mechanisms in endocrinology: primary HT and risk for breast cancer: a systematic review and meta-analysis[J]. European journal of endocrinology, 2012, 166(3): 373-381. DOI:10.1530/EJE-11-0838.
[10] PRINZI N, SORRENTI S, BALDINI E, et al. Association of Thyroid Diseases with Primary Extra-Thyroidal Malignancies in Women: Results of a Cross-Sectional Study of 6,386 Patients[J/OL]. PLOS ONE, 2015, 10(3): e0122958.DOI:10.1371/journal.pone.0122958.

[11] SHI X Z, ** X, XU P, et al. Relationship between breast cancer and levels of serum thyroid hormones and antibodies: a meta-analysis[J]. Asian Pacific Journal of Cancer Prevention, 2014, 15(16): 6643-6647. DOI:10.7314/APJCP.2014.15.16.6643
[12] MULLER I, KILBURN L S, TAYLOR P N, et al. TPOAb and thyroid function are not associated with breast cancer outcome: evidence from a large-scale study using data from the Taxotere as adjuvant chemotherapy trial (TACT, CRUK01/001)[J]. European thyroid journal, 2017, 6(4): 197-207. DOI:10.1159/000460246
[13] CHAN Y X, KNUIMAN M W, DIVITINI M L, et al. Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer[J].European journal of endocrinology, 2017, 177(4): 297-308. DOI:10.1530/EJE-17-0197.
[14] NOSRATZEHI S, HASHEMI S M, PAYANDEH A, et al. The relationship between breast cancer and thyroid autoimmune disorders in southeast Iran: A case-control study[J/OL]. Endocrine Regulations, 2024, 58(1): 20240030. DOI:10.2478/enr-2024-0030.
[15] GÓMEZ-IZQUIERDO J, FILION K B, BOIVIN J F, et al. Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic review[J/OL]. BMC Endocrine Disorders, 2020, 20(1): 83. DOI:10.1186/s12902-020-00566-9.
[16] HOLSBERGER D R, COOKE P S. Understanding the role of thyroid hormone in Sertoli cell development: a mechanistic hypothesis[J/OL]. Cell and Tissue Research, 2005,322(1): 133-140. DOI:10.1007/s00441-005-1082-z.
[17] ZHANG B, ZHANG A, ZHOU X, et al. Thyroid hormone analogue stimulates keratinocyte proliferation but inhibits cell differentiation in epidermis[J]. International journal of immunopathology and pharmacology, 2012, 25(4): 859-869.DOI:10.1177/039463201202500404
[18] KRASHIN E, PIEKIEŁKO-WITKOWSKA A, ELLIS M, et al. Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies[J/OL]. Frontiers in Endocrinology, 2019, 10: 59. DOI:10.3389/fendo.2019.00059.
[19] DAVIS P J, LIN H Y, HERCBERGS A A, et al. How thyroid hormone works depends on cell type, receptor type, and hormone analogue: Implications in cancer growth[J].Discovery medicine, 2019, 27(147): 111-117.
[20] CHEN L han, XIE T, LEI Q, et al. A review of complex hormone regulation in thyroid cancer: novel insights beyond the hypothalamus–pituitary–thyroid axis[J/OL].Frontiers in Endocrinology, 2024, 15[2025-04-18]. DOI:10.3389/fendo.2024.1419913.
[21] LIN H Y, CHIN Y T, YANG Y C S H, et al. Thyroid Hormone, Cancer, and Apoptosis[J/OL]. Comprehensive Physiology, 2016, 6(3): 1221-1237. DOI:10.1002/j.2040-4603.2016.tb00712.x.
[22] NISMAN B, ALLWEIS T M, CARMON E, et al. Elevated free triiodothyronine is associated with increased proliferative activity in triple-negative breast cancer[J]. Anticancer Research, 2021, 41(2): 949-954.DOI: 10.21873/anticanres.14848.
[23] BOLF E L, GILLIS N E, BARMUM M S, et al. The thyroid hormone receptor-RUNX2 Axis: a novel tumor suppressive pathway in breast cancer[J]. Hormones and Cancer,2020, 11: 34-41.DOI:10.1007/s12672-019-00373-2.
[24] BOLF E L, GILLIS N E, DAVIDSON C D, et al. Common tumor ‐suppressive signaling of thyroid hormone receptor beta in breast and thyroid cancer cells[J/OL]. Molecular Carcinogenesis, 2021, 60(12): 874-885. DOI:10.1002/mc.23352.
[25] TAWFIK I, SCHLICK K, OSTAKU J, et al. Breast cancer cells utilize T3 to trigger proliferation through cellular Ca2+ modulation[J/OL]. Cell Communication and Signaling,2024, 22(1): 533. DOI:10.1186/s12964-024-01917-y.
[26] STERLE H A, HILDEBRANDT X, ÁLVAREZ M V, et al. Thyroid status regulates the tumor microenvironment delineating breast cancer fate[J]. Endocrine-Related Cancer,2021, 28(7): 403-418.DOI: 10.1530/ERC-20-0277
[27] KLUBO-GWIEZDZINSKA J. Thyroid Hormones Enhance the Growth of Estrogen Receptor–Positive Breast Cancers[J/OL]. Clinical Thyroidology, 2022, 34(7): 286-289.DOI:10.1089/ct.2022;34.286-289.
[28] ASHIFKHAN M, BHURANI D, Agarwal N B. Alteration of thyroid function in Indian HER 2-negative breast cancer patients undergoing chemotherapy[J]. Asian Pacific Journal of Cancer Prevention, 2015, 16(17): 7701-7705.DOI:10.7314/APJCP.2015.16.17.7701
[29] FANG Y, YAO L, SUN J, et al. Does thyroid dysfunction increase the risk of breast cancer? A systematic review and meta-analysis[J]. Journal of endocrinological investigation,2017, 40: 1035-1047. DOI:10.1007/s40618-017-0679-x.